The application of 3 kinds of anticoagulant of Hisilicon for yidusaban tablets of p-toluenesulfonate was accepted
-
Last Update: 2015-01-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Edoxaban is a small molecule oral anticoagulant developed by Japan's first three Co., Ltd., which is an inhibitor of clotting factor X (FXa) and went on the market in April 2011 It can prevent VTE after total knee arthroplasty, total hip arthroplasty and hip fracture, and prevent ischemic stroke caused by atrial fibrillation It has been proved that the effect of oral etoxaban on VTE is better than that of enoxaparin According to the data, in 2011, the global sales volume of yidushaban was 16 million US dollars According to the forecast of balek capital, by 2016, the global anticoagulant market sales will reach US $15 billion, among which the new oral XA factor inhibitors and direct thrombin inhibitors will occupy 55% of the market share, while enoxaparin sodium and other injection anticoagulants will occupy 45% Hisilicon is mainly engaged in the production and sales of chemical preparations and APIs, and is the leader in the field of parenteral nutrition drugs, characteristic anti infective drugs and drugs for liver and gall diseases in China In the prospectus, the company has said that it will focus on tracking the development trend of innovative generic drugs in the international mainstream market, and establish the domestic leading new drug variety reserve resources.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
